Statin Therapy and Decreased Incidence of Positive Candida Cultures Among Patients With Type 2 Diabetes Mellitus Undergoing Gastrointestinal Surgery
OBJECTIVE To assess whether statin therapy decreases the incidence of cultures positive for Candida species among high-risk hospitalized patients with type 2 diabetes mellitus (DM). PATIENTS AND METHODS We performed a retrospective cohort study analyzing the records of all patients with type 2 DM wh...
Saved in:
Published in | Mayo Clinic proceedings Vol. 85; no. 12; pp. 1073 - 1079 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Rochester, MN
Elsevier Inc
01.12.2010
Mayo Foundation Elsevier, Inc Elsevier Limited Mayo Foundation for Medical Education and Research |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | OBJECTIVE To assess whether statin therapy decreases the incidence of cultures positive for Candida species among high-risk hospitalized patients with type 2 diabetes mellitus (DM). PATIENTS AND METHODS We performed a retrospective cohort study analyzing the records of all patients with type 2 DM who were admitted to Massachusetts General Hospital for lower gastrointestinal tract surgery between January 1, 2001, and May 1, 2008. We defined statin exposure as the filling of at least 1 prescription of statins during the 6 months before hospitalization or during the current hospital stay. The primary outcome was a culture positive for Candida species during hospitalization. Clinical information on a wide range of covariates was collected. Logistic regression analysis was used to adjust for possible confounders. RESULTS Of the 1019 patients who were eligible for the study, 493 (48%) were receiving statins. A total of 139 patients (14%) had at least 1 culture positive for Candida species during hospitalization. An adjusted multivariate model based on a backward stepwise elimination procedure showed that statin therapy significantly decreased the incidence of cultures positive for Candida species (odds ratio, 0.60; 95% confidence interval [CI], 0.38-0.96; P =.03) with a statistically significant prolonged time to event compared with no statin therapy (adjusted hazard ratio, 0.62; 95% CI, 0.44-0.88; P =.01). The benefit of statins was more prominent in patients with type 2 DM who had greater comorbidities (Charlson Comorbidity Index ≥2) (adjusted odds ratio, 0.47; 95% CI, 0.27-0.79; P =.01). CONCLUSION Among patients with type 2 DM who underwent gastrointestinal surgery, use of statins correlated with a decreased incidence of cultures positive for Candida species. |
---|---|
Bibliography: | Dr Mylonakis has received research support from Astellas Pharma US and was a member of the speaker's bureau for Pfizer. Dr Peleg has acted as an advisor to Abbott Molecular and Ortho-McNeil-Janssen. None of the funders was involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript. |
ISSN: | 0025-6196 1942-5546 |
DOI: | 10.4065/mcp.2010.0447 |